CorMedix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Benzinga

03-24

CorMedix Inc. (NASDAQ:CRMD) will release its fourth-quarter financial results, before the opening bell, on Tuesday, March 25.

Analysts expect the Berkeley Heights, New Jersey-based company to report quarterly earnings at 14 cents per share, versus a year-ago loss of 26 cents per share in the year-ago period. CorMedix projects quarterly revenue of $28.34 million, according to data from Benzinga Pro.

On Jan. 21, CorMedix disclosed that it has engaged with WSI PBG to promote DefenCath® to healthcare providers in facilities operated by the Department of Veterans Affairs and other federal facilities.

CorMedix shares gained 0.5% to close at $10.91 on Friday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

Needham analyst Serge Belanger maintained a Buy rating and increased the price target from $10 to $18 on Oct. 31, 2024. This analyst has an accuracy rate of 69%.
Truist Securities analyst Joon Lee maintained a Buy rating and raised the price target from $12 to $17 on Oct. 22, 2024. This analyst has an accuracy rate of 78%.

Considering buying CRMD stock? Here’s what analysts think:

Read This Next:

How To Earn $500 A Month From KB Home Stock Ahead Of Q1 Earnings

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2521721312"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2521721312\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2521721312?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-24 21:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2521721312","market":"hk","top_or_hot":-1,"title":"CorMedix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call","media":"Benzinga","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/CRMD\">CorMedix Inc.</a></strong> (NASDAQ:CRMD) will release its fourth-quarter financial results, before the opening bell, on Tuesday, March 25.</p>\n<p>Analysts expect the Berkeley Heights, New Jersey-based company to report quarterly earnings at 14 cents per share, versus a year-ago loss of 26 cents per share in the year-ago period. CorMedix projects quarterly revenue of $28.34 million, according to data from Benzinga Pro.</p>\n<p>On Jan. 21, CorMedix disclosed that it has engaged with WSI PBG to promote DefenCath® to healthcare providers in facilities operated by the Department of Veterans Affairs and other federal facilities.</p>\n<p>CorMedix shares gained 0.5% to close at $10.91 on Friday.</p>\n<p>Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.</p>\n<p>Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.</p>\n<ul>\n<li>Needham analyst Serge Belanger maintained a Buy rating and increased the price target from $10 to $18 on Oct. 31, 2024. This analyst has an accuracy rate of 69%.</li>\n<li>Truist Securities analyst Joon Lee maintained a Buy rating and raised the price target from $12 to $17 on Oct. 22, 2024. This analyst has an accuracy rate of 78%.</li>\n</ul>\n<p>Considering buying CRMD stock? Here’s what analysts think: </p>\n<figure><img decoding=\"async\" height=\"583\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/24042017/image-210-1024x583.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/24042017/image-210-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/24042017/image-210-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/24042017/image-210-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/24042017/image-210.png 1116w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong>How To Earn $500 A Month From <a href=\"https://laohu8.com/S/KBH\">KB Home</a> Stock Ahead Of Q1 Earnings</strong></li>\n</ul></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CorMedix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorMedix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2025-03-24 21:21</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<html><body><p><strong><a href=\"https://laohu8.com/S/CRMD\">CorMedix Inc.</a></strong> (NASDAQ:CRMD) will release its fourth-quarter financial results, before the opening bell, on Tuesday, March 25.</p>\n<p>Analysts expect the Berkeley Heights, New Jersey-based company to report quarterly earnings at 14 cents per share, versus a year-ago loss of 26 cents per share in the year-ago period. CorMedix projects quarterly revenue of $28.34 million, according to data from Benzinga Pro.</p>\n<p>On Jan. 21, CorMedix disclosed that it has engaged with WSI PBG to promote DefenCath® to healthcare providers in facilities operated by the Department of Veterans Affairs and other federal facilities.</p>\n<p>CorMedix shares gained 0.5% to close at $10.91 on Friday.</p>\n<p>Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.</p>\n<p>Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.</p>\n<ul>\n<li>Needham analyst Serge Belanger maintained a Buy rating and increased the price target from $10 to $18 on Oct. 31, 2024. This analyst has an accuracy rate of 69%.</li>\n<li>Truist Securities analyst Joon Lee maintained a Buy rating and raised the price target from $12 to $17 on Oct. 22, 2024. This analyst has an accuracy rate of 78%.</li>\n</ul>\n<p>Considering buying CRMD stock? Here’s what analysts think: </p>\n<figure><img decoding=\"async\" height=\"583\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/24042017/image-210-1024x583.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/24042017/image-210-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/24042017/image-210-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/24042017/image-210-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/24042017/image-210.png 1116w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong>How To Earn $500 A Month From <a href=\"https://laohu8.com/S/KBH\">KB Home</a> Stock Ahead Of Q1 Earnings</strong></li>\n</ul></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRMD","symbol_name":"CorMedix Inc.","start_time":0,"source_url":"https://www.benzinga.com/analyst-ratings/price-target/25/03/44457886/cormedix-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call","article_id":"2521721312","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2521721312","pubTimestamp":1742822511,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":" ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CRMD":"CorMedix Inc."},"translate_title":"CorMedix盈利迫在眉睫；这些最准确的分析师在收益看涨期权之前修改了预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRMD":0.9},"content_text":"CorMedix Inc. (NASDAQ:CRMD) will release its fourth-quarter financial results, before the opening bell, on Tuesday, March 25.\nAnalysts expect the Berkeley Heights, New Jersey-based company to report quarterly earnings at 14 cents per share, versus a year-ago loss of 26 cents per share in the year-ago period. CorMedix projects quarterly revenue of $28.34 million, according to data from Benzinga Pro.\nOn Jan. 21, CorMedix disclosed that it has engaged with WSI PBG to promote DefenCath® to healthcare providers in facilities operated by the Department of Veterans Affairs and other federal facilities.\nCorMedix shares gained 0.5% to close at $10.91 on Friday.\nBenzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.\nLet's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.\n\nNeedham analyst Serge Belanger maintained a Buy rating and increased the price target from $10 to $18 on Oct. 31, 2024. This analyst has an accuracy rate of 69%.\nTruist Securities analyst Joon Lee maintained a Buy rating and raised the price target from $12 to $17 on Oct. 22, 2024. This analyst has an accuracy rate of 78%.\n\nConsidering buying CRMD stock? Here’s what analysts think: \n\nRead This Next: \n\nHow To Earn $500 A Month From KB Home Stock Ahead Of Q1 Earnings","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}